|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1000 Mylan Boulevard |
Address2 |
|
| City | Canonsburg |
State | PA |
Zip Code | 15317 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 26353-12
|
||||||||
|
6. House ID# 337920000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Peter Wallace |
Date | 4/20/2020 5:02:54 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs
Generic drug quality and FDA oversight
Medicare reimbursement for biosimilars, shared savings for Part B providers
S.2543, Prescription Drug Pricing Reduction Act
S. 1416, Affordable Prescriptions for Patients Act
S. 1895 Lower Health Care Costs Act of 2019
H.R. 3- Lower Drug Costs Now Act of 2019
H.R. 938 - BLOCKING Act of 2019
H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019
Part D Formulary Design and Generic Drug Tiering
H.R. 4913 - Ensuring Access to Lower-Cost Medicines for Seniors Act
H.R. 4455 - BIOSIM Act
H.R. 4629 - Star Rating for Biosimilars Act
H.R. 6179 - Increasing Access to Biosimilars Act of 2020
S. 2723 - Mitigating Emergency Drug Shortages Act
H.R. 5304 - PBM Transparency in Prescription Drug Costs Act
H.R. 748 - CARES Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), White House Office, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katharine |
Hayes |
|
|
|
Akshai |
Datta |
|
|
|
David |
Marin |
|
|
|
Peter |
Wallace |
|
|
|
Anne |
Wilson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Akshai |
Datta |
|
|
|
David |
Marin |
|
|
|
Peter |
Wallace |
|
|
|
Katharine |
Hayes |
|
|
|
Anne |
Wilson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs
S.344, H.R. 990 - Hatch-Waxman Integrity Act of 2019
Patent Settlements
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Marin |
|
|
|
Peter |
Wallace |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trade issues related to generic medicines
Access to global pharmaceutical supply chain
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), U.S. Trade Representative (USTR), Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Wallace |
|
|
|
Akshai |
Datta |
|
|
|
Katharine |
Hayes |
|
|
|
David |
Marin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIN
16. Specific lobbying issues
Policy and oversight related to proxy advisory firms
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Marin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
| Mylan NV |
|
|
0 | 100 % | ||||||||||
| Mylan Holdings Limited |
|
|
0 | 100 % | ||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |